促销时间表 Cybin Inc.
先进的时间表
简单图表
关于公司 Cybin Inc.
Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in Phase 1/2a clinical trial to treat major depressive and alcohol use disorders; CYB004, a deuterated dimethyltryptamine, which is in Phase 1 clinical trial for treating generalized anxiety disorders; and CYB005, a phenethylamine derivative, which in in preclinical stage to treat neuroinflammation. 更多详情| IPO date | 2019-09-13 |
|---|---|
| ISIN | CA23256X1006 |
| Industry | Biotechnology |
| Sector | Health Care |
| Валюта | usd |
| Валюта отчета | cad |
| Сайт | https://www.cybin.com |
| Цена ао | 7.3 |
| 每日价格变化: | +3.7% (7.3) |
|---|---|
| 每周价格变化: | +3.84% (7.29) |
| 每月价格变化: | -19.12% (9.36) |
| 3个月内价格变化: | -22.6% (9.78) |
| 六个月内的价格变化: | -2.35% (7.752) |
| 每年价格变化: | +1 610.73% (0.4425) |
| 3年内价格变化: | +870.51% (0.78) |
| 5年内价格变化: | +3 738.74% (0.1972) |
| 年初以来价格变化: | -18.78% (9.32) |
|
|
低估
|
效率
|
|||||||||||||||||||||||||||||||||||||
股息
|
责任
|
成长冲动
|
|||||||||||||||||||||||||||||||||||||
| 机构 | 体积 | 分享, % |
|---|---|---|
| Point72 Asset Management, L.P. | 30061112 | 4.04 |
| Anson Funds Management LP | 8924494 | 1.2 |
| Alyeska Investment Group, L.P. | 5683196 | 0.76 |
| CVI Holdings, LLC | 5225262 | 0.7 |
| AdvisorShares Investments, LLC | 1859181 | 0.25 |
| PDS Planning, Inc | 1153120 | 0.16 |
| Propel Bio Management, LLC | 850000 | 0.11 |
| Simplify Asset Management, Inc. | 500000 | 0.07 |
| FNY Investment Advisers, LLC | 402000 | 0.05 |
| Lewis Asset Management, LLC | 282000 | 0.04 |
| 导师 | 职称 | 支付 | 出生年份 |
|---|---|---|---|
| Mr. Eric So L.L.B. | Co-Founder, President & Executive Chairman | 458.88k | 1976 (49 年) |
| Mr. Douglas L. Drysdale | Chief Executive Officer | 613.44k | 1970 (55 年) |
| Mr. Paul Glavine | Co-Founder, Chief Growth Officer & Director | 458.88k | 1989 (36 年) |
| Mr. Greg Cavers | Chief Financial Officer | 242.09k | 1971 (54 年) |
| Mr. Aaron Bartlone | Chief Operating Officer | 379.12k | 1967 (58 年) |
| Mr. John Kanakis | Co-Founder | 704.03k | 1981 (44 年) |
| Dr. Alex L. Nivorozhkin Ph.D. | Chief Scientific Officer | N/A | 1960 (65 年) |
| Ms. Lori Challenger | Chief Compliance, Ethics & Administrative Officer | N/A | |
| Mr. Gabriel Fahel | Chief Legal Officer & Corporate Secretary | N/A | 1976 (49 年) |
| Mr. George Tziras | Chief Business Officer & Director | 1981 (44 年) |
